Green Arrow Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Green Arrow Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-130,000	Closed	-$9.38M	–	133
2014 Q3	$9.38M	Buy	130,000 +80,000	+160%	+$5.26M	0.79%	31
2014 Q2	$3.11M	Buy	50,000 +10,000	+25%	+$604K	0.39%	74
2014 Q1	$2.73M	Sell	40,000 -37,071	-48%	-$2.73M	0.23%	135
2013 Q4	$5.42M	Buy	+77,071	New	+$5.23M	0.38%	93
2013 Q3	–	Sell	-125,000	Closed	-$6.97M	–	259
2013 Q2	$6.97M	Buy	+125,000	New	+$7.79M	0.56%	44

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Green Arrow Capital Management's BMRN Position: Q4 2014 in Review

Green Arrow Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2014, closing a stake of 130,000 shares — an estimated $9.38M sold.

Green Arrow Capital Management first reported a position in BMRN in Q2 2013 and held it in 5 quarters. The position peaked at $9.38M in Q3 2014. 342 funds tracked by Wall St. Rank hold BMRN as of Q4 2014.

Green Arrow Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
Green Arrow Capital Management sold 130,000 BioMarin Pharmaceuticals shares in Q4 2014, an estimated $9.38M.
Green Arrow Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 5 quarters.
Green Arrow Capital Management's BioMarin Pharmaceuticals position peaked at $9.38M in Q3 2014.
342 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2014.

Based on Green Arrow Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.